Predicting hepcidin level using inflammation markers and iron indicators in patients with anemia of chronic disease

Suega, Ketut; Widiana, Gde Raka

doi:10.1016/j.htct.2019.03.011

Cited by 18 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CRP is a very sensitive indicator of inflammatory response in the body and is closely related to IL-6 and both involved in the development of cancer-associated anemia [13]. SF in the body is also an acute phase reactant for inflammation and stress [14,15].…”

Section: Introductionmentioning

confidence: 99%

Expression of serum BMP6 and hepcidin in cancer-related anemia

Zhang

Yan

et al. 2020

Hematology

View full text Add to dashboard Cite

Objective: To study the function of human bone morphogenetic protein-6 (BMP6) and hepcidin in cancer-related anemia. Methods: The levels of Hemoglobin (Hb), serum C-reactive protein (CRP), BMP6, hepcidin and ferritin (SF) were measured in 115 patients with solid tumors, who were divided into elevated CRP group and normal CRP group, and further divided into anemia subgroup and non-anemia subgroup according to the CRP level. Results: The prevalence of anemia was 53.9% in all patients. In the elevated CRP group, the levels of CRP, hepcidin and SF of the anemia subgroup were higher than the non-anemia subgroup (P < 0.05); the BMP6 levels had no difference between the subgroups (P > 0.05). In the normal CRP group, the BMP6 level in the anemia subgroup was higher than the nonanemia subgroup (P < 0.01); the CRP, hepcidin and SF levels showed no difference between the subgroups (P > 0.05). Among the 115 patients, CRP and SF were both positively correlated with hepcidin (P < 0.05), and CRP and hepcidin were negatively correlated with Hb (P < 0.05), while SF had no correlation with Hb (P > 0.05); BMP6 was negatively correlated with Hb (P < 0.05) while had no correlation with CRP, hepcidin and SF (P < 0.05). Conclusions: The occurrence of anemia in patients with elevated CRP is associated with hepcidin over-expression, while in patients with normal CRP is associated with BMP6 overexpression. We speculate BMP6 and hepcidin likely play different roles in the occurrence of cancer-related anemia.

show abstract

Section: Introductionmentioning

confidence: 99%

Expression of serum BMP6 and hepcidin in cancer-related anemia

Zhang

Yan

et al. 2020

Hematology

View full text Add to dashboard Cite

show abstract

“…The antiinflammatory and antioxidant effects of desidustat are reported ( Joharapurkar et al., 2021 ) which indicates that stabilization of HIF by desidustat can reduce the production of inﬂammatory cytokines. Increase in inflammatory interleukin cytokines is reported in EPO resistance ( Macdougall and Cooper, 2002 ; Pesce et al., 2014 ) and decrease in these markers is also correlated with reduction in the hepcidin levels ( Suega and Widiana, 2019 ). However, further probe into the antiinflammatory mechanism of action of desidustat is warranted.…”

Section: Discussionmentioning

confidence: 99%

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state

Joharapurkar

Patel

Kshirsagar

et al. 2022

Current Research in Pharmacology and Drug Discovery

View full text Add to dashboard Cite

“…Although studies in human subjects are in favor of this scenario, as an increase in serum hepcidin has been reported in cases of septic patients or patients under chronic inflammatory conditions [ 7 , 9 , 17 , 18 ], a direct link between invading pathogens and hepcidin upregulation has not been easily or firmly established due to a lack of prospective studies. Retrospective studies cannot easily exclude the possibility that the high levels of hepcidin observed in patients are not a result of the disease, but rather of a preexisting condition caused by a disorder in iron homeostasis and related to the pathogenicity of or the susceptibility to the disease.…”

Section: Discussionmentioning

confidence: 99%

Hepcidin as a Sensitive and Treatment-Responsive Acute-Phase Marker in Patients with Bacteremia: A Pilot Study

et al. 2022

View full text Add to dashboard Cite

Hepcidin regulates iron metabolism by inhibiting intestinal iron absorption and iron release from iron stores. In addition to iron overload, inflammatory conditions also up-regulate hepcidin synthesis, which may serve as an antimicrobial defense by reducing iron availability to the invading microbes. The purpose of this study is to test this hypothesis in human patients by determining serum hepcidin concentration by enzyme linked immunosorbent assay (ELISA) in healthy blood donors (n = 60) and patients hospitalized because of bacteremia (n = 50), before (day 0) and after seven days (day 7) of appropriate antibiotic treatment. Serum hepcidin was significantly increased in patients with bacteremia, both at day 0 and at day 7, compared to healthy controls. However, there was significant reduction of serum hepcidin after 7-day treatment, in concert with changes in serum C-reactive protein (CRP). The hepcidin changes were similar for both Gram-negative and Gram-positive single infection cases, while CRP was significantly reduced only in the former. In contrast to hepcidin, the levels of serum ferritin in the patients remained high after treatment, irrespective of infection type. These data confirm the stimulation of hepcidin secretion in human subjects upon different types of systemic microbial infection and suggest that hepcidin is a more sensitive and treatment-responsive acute-phase marker than ferritin in bacteremia, which needs to be explored with bigger-sized and better-matched patient cohorts.

show abstract

Predicting hepcidin level using inflammation markers and iron indicators in patients with anemia of chronic disease

Cited by 18 publications

References 27 publications

Expression of serum BMP6 and hepcidin in cancer-related anemia

Expression of serum BMP6 and hepcidin in cancer-related anemia

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state

Hepcidin as a Sensitive and Treatment-Responsive Acute-Phase Marker in Patients with Bacteremia: A Pilot Study

Contact Info

Product

Resources

About